Skip to content
OpenCapital
Get started

Tarsus Pharmaceuticals, Inc. TARS Q1 2026 earnings

Reported May 6, 2026 · After market close

Revenue$162.1MBeat by $12.5M
EPS-$0.16Beat by $0.24
Revenue estimate$149.6M
EPS estimate-$0.40

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$169.1M
EPS estimate-$0.21

Financials

Q1 2026

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$2.62B+49.5%
Enterprise value$2.61B+51.0%
P/S4.9×-1.0×

Profitability

See full
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Segments

By segment

See full
Reportable Segment$162.1M+107%

Versus estimates

Revenue

Q1 2026$162.1MBeat by $12.5M
Q4 2025$151.7MBeat by $7.1MQ3 2025$118.7MMiss by $25.9MQ2 2025$102.7MMiss by $10.4MQ1 2025$78.3MMiss by $20.8MQ4 2024$66.4MBeat by $2.0M

Diluted EPS

Q1 2026-$0.16Beat by $0.24
Q4 2025-$0.20Miss by $0.10Q3 2025-$0.30Beat by $0.05Q2 2025-$0.48Miss by $0.15Q1 2025-$0.64Beat by $0.05Q4 2024-$0.60Beat by $0.08

Ask the moment Tarsus Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Tarsus Pharmaceuticals, Inc. report Q1 2026 earnings?
Tarsus Pharmaceuticals, Inc. (TARS) reported Q1 2026 earnings on May 6, 2026 after market close.
What were Tarsus Pharmaceuticals, Inc.'s Q1 2026 revenue and EPS?
Tarsus Pharmaceuticals, Inc. reported revenue of $162.1M and eps of $-0.16 for Q1 2026.
Did Tarsus Pharmaceuticals, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $149.6M by $12.5M. EPS beat the consensus estimate of $-0.40 by $0.24.
How did Tarsus Pharmaceuticals, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 106.9% from $78.3M a year earlier and eps grew 75.0% from $-0.64.
Where can I find Tarsus Pharmaceuticals, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001819790-26-000037) and the 10-Q periodic report (0001819790-26-000038) directly on SEC EDGAR. The filing index links above go to sec.gov.